Seung Yeon Oh

Seung Yeon Oh

Auto-generated profile, based on publicly available information

Seung Yeon Oh

Department of Biomedical Science Institute, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, Republic of Korea

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2022 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
SOSeung Yeon Oh
Seung Yeon Oh
YLYou Won Lee
You Won Lee
ELEun Ji Lee
Eun Ji Lee
JKJae Hwan Kim
Jae Hwan Kim
YPYoungJoon Park
YoungJoon Park
MYMi Ran Yun
Mi Ran Yun
Purpose: MET amplification is a frequent mechanism of resistance to EGFR tyrosine kinase inhibitors (TKI) in patients with EGFR-mutated non–small cell lung cancer (NSCLC), and combined treatment with EGFR TKIs and MET TKIs has been explored as a strategy to overcome resistance. However, durable response is invariably limited by the emergence of acquired resistance. Here, we investigated the preclinical activity of REGN5093-M114, a novel antibody–drug conjugate targeting MET in MET-driven patient-derived models. Experimental Design: Patient-derived organoids, patient-derived cells, or ATCC cell lines were used to investigate the in vitro/in vivo activity of REGN5093-M114. Results: REGN5093-M114 exhibited significant antitumor efficacy compared with MET TKI or unconjugated METxMET biparatopic antibody (REGN5093). Regardless of MET gene copy number, MET-overexpressed TKI-naïve EGFR-mutant NSCLC cells responded to REGN5093-M114 treatment. Cell surface MET expression had the most predictive power in determining the efficacy of REGN5093-M114. REGN5093-M114 potently reduced tumor growth of EGFR-mutant NSCLC with PTEN loss or MET Y1230C mutation after progression on prior osimertinib and savolitinib treatment. Conclusions: Altogether, REGN5093-M114 is a promising candidate to overcome the challenges facing functional MET pathway blockade.

8 February 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
ELEun Ji Lee
Eun Ji Lee
SOSeung Yeon Oh
Seung Yeon Oh
YLYou Won Lee
You Won Lee
JKJu Young Kim
Ju Young Kim
MKMin-Je Kim
Min-Je Kim
BCByoung Chul Cho
Byoung Chul Cho
Purpose: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) serve as the standard first-line therapy for EGFR-mutated non-small cell lung cancer (NSCLC). Despite the sustained clinical benefits achieved through optimal EGFR-TKI treatments, including the third-generation EGFR-TKI osimertinib, resistance inevitably develops. Currently, there are no targeted therapeutic options available postprogression on osimertinib. Here, we assessed the preclinical efficacy of BI-4732, a novel fourth-generation EGFR-TKI, using patient-derived preclinical models reflecting various clinical scenarios. Experimental Design: The antitumor activity of BI-4732 was evaluated using Ba/F3 cells and patient-derived cell/organoid/xenograft models with diverse EGFR mutations. Intracranial antitumor activity of BI-4732 was evaluated in a brain-metastasis mouse model. Results: We demonstrated the remarkable antitumor efficacy of BI-4732 as a single agent in various patient-derived models with EGFR_C797S-mediated osimertinib resistance. Moreover, BI-4732 exhibited activity comparable to osimertinib in inhibiting EGFR-activating (E19del and L858R) and T790M mutations. In a combination treatment strategy with osimertinib, BI-4732 exhibited a synergistic effect at significantly lower concentrations than those used in monotherapy. Importantly, BI-4732 displayed potent antitumor activity in an intracranial model, with low efflux at the blood–brain barrier. Conclusions: Our findings highlight the potential of BI-4732, a selective EGFR-TKI with high blood–brain barrier penetration, targeting a broad range of EGFR mutations, including C797S, warranting clinical development.

13 March 2026 in Clinical Cancer Research
Verified
Journal Article
Open access
ELEun Ji Lee
Eun Ji Lee
JKJi Ae Ko
Ji Ae Ko
MKMin-Je Kim
Min-Je Kim
JCJae Seok Cho
Jae Seok Cho
JHJi-Youn Han
Ji-Youn Han
SLSun Min Lim
Sun Min Lim
Purpose: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKI) have revolutionized the treatment of non–small cell lung cancer (NSCLC) with activating EGFR mutations. However, acquired resistance—particularly the EGFR C797S mutation—remains a major clinical challenge. As no approved targeted therapies are available following disease progression on the third-generation EGFR-TKI osimertinib, this study aimed to evaluate JIN-A02, a novel fourth-generation EGFR-TKI, as a therapeutic strategy to overcome C797S-mediated resistance. Experimental Design: JIN-A02, a fourth-generation EGFR TKI, was evaluated for its antitumor efficacy and blood–brain barrier penetration in in vitro and in vivo models of NSCLC harboring EGFR C797S and T790M mutations. Results: JIN-A02 demonstrated potent antiproliferative activity in preclinical NSCLC models harboring EGFR C797S and T790M mutations, with superior inhibition of EGFR signaling compared with osimertinib. In both subcutaneous and orthotopic intracranial xenograft models, JIN-A02 elicited substantial tumor regression, indicating robust in vivo efficacy. The agent was well tolerated throughout the treatment period without notable toxicity. In line with preclinical data, early clinical trial data showed signs of efficacy, including three patients showing partial response. Conclusions: These findings highlight JIN-A02 as a promising therapeutic strategy to overcome C797S- and T790M-mediated resistance in EGFR-mutant NSCLC, including intracranial disease, and support its further clinical development.

25 November 2025
Verified
Other
Open access
SOSeung Yeon Oh
Seung Yeon Oh
YLYou Won Lee
You Won Lee
ELEun Ji Lee
Eun Ji Lee
JKJae Hwan Kim
Jae Hwan Kim
YPYoungJoon Park
YoungJoon Park
MYMi Ran Yun
Mi Ran Yun
(A-B) Each cell viability was measured after treatment with REGN 5093-M114 for 5 days, capmatinib and tepotinib for 3 days. REGN 5093-M114 was treated with concentration of 0 µg/ml, 0.03 µg/ml, 0.1 µg/ml, 0.3 µg/ml, 1 µg/ml, 3 µg/ml. MET TKIs, capmatinib and tepotinib were treated with serial concentrations from 0nM to 100nM.

25 November 2025
Verified
Other
Open access
SOSeung Yeon Oh
Seung Yeon Oh
YLYou Won Lee
You Won Lee
ELEun Ji Lee
Eun Ji Lee
JKJae Hwan Kim
Jae Hwan Kim
YPYoungJoon Park
YoungJoon Park
MYMi Ran Yun
Mi Ran Yun
Genomic landscape in patient-derived preclinical models. The genetic alteration of the PDC (patient-derived cell), PDO (patient-derived organoid), and PDX (patient-derived xenograft) models are shown as an oncoprint plot.

25 November 2025
Verified
Other
Open access
SOSeung Yeon Oh
Seung Yeon Oh
YLYou Won Lee
You Won Lee
ELEun Ji Lee
Eun Ji Lee
JKJae Hwan Kim
Jae Hwan Kim
YPYoungJoon Park
YoungJoon Park
MYMi Ran Yun
Mi Ran Yun
Cells were seeded on a 96-well plate and incubated with the REGN5093-M114, Control Ab-M114, and EGFR TKIs (osimertinib, lazertinib). Cell viability was measured after 5 days of REGN5093-M114 treatment and 3 days of capmatinib treatment via CellTiter-Glo. The curved graphs show the cell viability results for a single drug, and the bar-graphs show the cell viability for the combination of two drugs.